This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Heier, C. R. Articles by DiDonato, C. J. Search for Related Content PubMed PubMed Citation Articles by Heier, C. R. Articles by DiDonato, C. J. Social Bookmarking                   What's this?

SMN Transcript Stability: Could Modulation of Messenger RNA Degradation Provide a Novel Therapy for Spinal Muscular Atrophy?

Department of Pediatrics, Feinberg School of Medicine, Northwestern University, and the Human Molecular Genetics Program, Children's Memorial Research Center, Chicago, Illinois

Rocky G. Gogliotti, BS

Department of Pediatrics, Feinberg School of Medicine, Northwestern University, and the Human Molecular Genetics Program, Children's Memorial Research Center, Chicago, Illinois

Christine J. DiDonato, PhD

Department of Pediatrics, Feinberg School of Medicine, Northwestern University, and the Human Molecular Genetics Program, Children's Memorial Research Center, Chicago, Illinois, c-didonato{at}northwestern.edu

Proximal spinal muscular atrophy is caused by deletion or mutation of the survival motor neuron 1 gene, SMN1. Rentention of a nearly identical copy gene, SMN2, enables survival but is unable to fully compensate for the loss of SMN1. The SMN1 and SMN2 genes differ by a single nucleotide that results in alternative splicing of SMN2 exon 7 due to the disruption of a binding site for an essential splicing factor. This alternatively spliced form encodes a partially functional truncated protein. Because SMN2 is present in patients with spinal muscular atrophy, it is an ideal therapeutic target. Some of the current approaches to increase SMN protein levels are aimed at increasing the transcription from SMN2 or at preventing exon 7 skipping. One area that has yet to be investigated is the stability of messenger ribonucleic acid (RNA) transcripts produced from SMN2. We postulated that transcripts derived from SMN2 may be less stable because alternative splicing, recruitment of RNA-binding proteins, and alteration of stop codons have been associated with changes in rates of messenger RNA decay; these features are all characteristic of SMN2. Accordingly, transcript degradation was examined within primary fibroblast cells that exclusively contained SMN1 or SMN2 by treating cultures with a transcriptional inhibitor to observe messenger RNA stability. The results indicate that SMN transcript instability does not play a role in the disease mechanism, suggesting that therapeutic modulation of messenger RNA degradation would not target a molecular defect in patients with spinal muscular atrophy, although it could provide general benefits by increasing total pools of SMN2 transcripts.

Key Words: spinal muscular atrophy • SMN1 gene • SMN2 gene

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?